Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →MPM Capital LP led the round with $20 million. Co-investors included Alta Partners, Origin Capital Management LLC, and Quantum Partners LDC.
By December 2003, after another year with strong financial gains, Barr moved to acquire Endeavor Pharmaceuticals Inc. Endeavor was the developer of the…
In 2003, the company acquired Endeavor Pharmaceuticals for $35 million.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Barr acquired Endeavor for ~$35M in 2003. Smaller specialty/women's health add-on. Source: Barr Pharmaceuticals corporate history records, Wikipedia summary.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Barr Pharmaceuticals / Endeavor Pharmaceuticals (this deal) | 2003 | $35M | — |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| IDEC Pharmaceuticals Corporation / Biogen Inc. | 2003 | $6.5B | 77 |
| Johnson & Johnson / Crucell NV | 2003 | $2.4B | 75 |
← Browse all deals · How we score deals
More: 2003 deals